You are here


Fatty Acid Derivatives and Their Use

Researchers at the National Institutes on Aging (NIA) seek research co-development or licensees for novel compounds and pharmaceutical formulations to treat autoimmune disorder and inflammation. Other potential indications for these compounds include pain, itching, and/or skin disorders.
NIH Reference Number
Product Type
  • autoimmune, inflammation, pain, National Institutes on Aging (NIA), Ramsden
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

A significant challenge in developing therapies for the treatment and prevention of autoimmune, inflammatory, and pain disorders has been the discovery and selection of suitable compounds.
Researchers at NIA mitigated this issue in their development of novel compounds for treatment of these disorders.  NIA scientists discovered and synthesized novel fatty acid derivatives that may ameliorate these conditions.  The disclosed fatty acid derivatives have increased activity, lower toxicity, greater stability, and longer half-life in a relevant rat model. These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.  
The National Institute on Aging (NIA), a division of NIH, seeks statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.

Potential Commercial Applications
  • Autoimmune disorders
  • Inflammation
  • Pain-related disorders
  • Itching and/or skin disorders
Competitive Advantages
  • Readily cross the blood-brain barrier
  • Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain
  • Substantial intellectual property life cycle; e.g., patents if issued likely will expire no earlier than 2038
  • Proof-of-concept in rat model

Christopher Ramsden (NIA), Gregory Keyes (NIA)

Development Stage

Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.    [PMID: 28831021]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number US Provisional Application 62/529,846 , Filed 07 Jul 2017
Therapeutic Area
Wednesday, April 25, 2018